RxDoctor Payments Data

Jatin Amin, MD

Cardiovascular Disease · Monroe, MINPI 1710987060

Payments from drug & device makers

$3,886in general payments, 2019–2025

Across 18 payments — averaging $215.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$3K
  • Abbott$838
  • E.r. Squibb & Sons, L.L.C.$149
  • AstraZeneca$125
  • Atricure, Inc.$40
  • Boehringer Ingelheim$24
  • plus $42 from 2 others

What the payments were for

  • Travel & lodging$2,59967%
  • Food & beverage$1,28733%

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,886 in reported general payments places this provider in the 50th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$170,895
Medicare patients
623
Services billed
2,519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban290$333,271
EntrestoSacubitril/Valsartan72$93,498
XareltoRivaroxaban79$84,810
JardianceEmpagliflozin18$22,397
Diltiazem 24hr Er (Cd)Diltiazem Hcl180$6,522
Metoprolol Succinate333$6,005
Carvedilol426$5,350
Atorvastatin Calcium423$5,048
Amiodarone Hcl150$3,893
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide106$3,888
Valsartan62$3,044
Ranolazine ErRanolazine13$2,876
Losartan Potassium223$2,791
Nifedipine ErNifedipine84$2,462
Rosuvastatin Calcium142$2,456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$18$93,49872 claims
Boehringer IngelheimJardiance$24$22,39718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Monroe

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →